He will also be ultimately responsible for ensuring the regulatory compliant execution of this trial and coordinating the multidisciplinary interactions of the investigators and administrators involved with this study. Overall coordination of the multi- site phase II trial will be assisted by Dr. G erald Grant, Stanford University (Neurosurgery Chair) and Sri Gururangan , University of Florida (Neuro -Oncology Chair). A Leadership Plan for this collaboration with Dr. Mitchell functioning as lead PI and Immunotherapy Chair has been developed and is out lined below (Section 21.1 Leadership Plan). William Slayton, M.D. is Professor, Division Chief, and Program Director of Pediatric Hematology/Oncology at the University of Florida with over 20 years of experience in the care of pediatric patients. Dr. Sla yton has an active clinical protocol involving the use of high- dose chemotherapy followed by autologous stem cell rescue in children with CNS tumors and extensive experience in treating children with CNS tumors using intensive chemotherapy that will be utilized as the backbone for the clinical trial design investigating the safety and immunologic effects of adoptive lymphocyte transfer and DC vaccination during hematopoietic Re-MATC H Protocol Page 97 of 106 Version: 20180628 recovery from high -dose chemotherapy. http://hemonc.pediatrics.med.ufl.edu/faculty -and-staff/attending - physicians/dr -william- slayton/ John R.